QC
CRBP icon

Quadrature Capital’s Corbus Pharmaceuticals CRBP Stock Holding History

Quadrature Capital’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$114K Sell
12,199
-10,787
-47% -$102K ﹤0.01% 1451
2026
Q1 		$216K Sell
22,986
-6,903
-23% -$58.1K ﹤0.01% 1096
2025
Q4 		$243K Buy
+29,889
New +$369K ﹤0.01% 917

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Quadrature Capital's CRBP Position: Q2 2026 in Review

Quadrature Capital reduced its Corbus Pharmaceuticals (CRBP) stake by 47% in Q2 2026, selling an estimated $102K and leaving 12,199 shares worth $114K. The position accounts for ﹤0.01% of the portfolio, ranked #1451.

Quadrature Capital first reported a position in CRBP in Q4 2025 and has held it in 3 quarters since. The position peaked at $243K in Q4 2025. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Quadrature Capital held 12,199 shares of Corbus Pharmaceuticals worth $114K as of Q2 2026.
  • Quadrature Capital sold 10,787 Corbus Pharmaceuticals shares in Q2 2026, an estimated $102K.
  • Corbus Pharmaceuticals made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1451 holding.
  • Quadrature Capital first reported a position in Corbus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Quadrature Capital's Corbus Pharmaceuticals position peaked at $243K in Q4 2025.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.